Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Matthew on +44 1494 818040 or matthew@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Matthew Moxon
Account Manager
matthew@zenopa.com
+44 1494 818040

Testimonials
Zenopa, thank you. You helped me getting the job of my dreams, the career of a lifetime. I have met many recruitment specialists but I guess where you difference yourself from all the others is that ...
Maria, 2013

Bausch and Lomb chief details growth plans

17 October 2011 00:00 in Medical Company Restructures


Bausch and Lomb's chief executive officer Brent Saunders has outlined plans to build on the company's foundations for growth in the coming years.

In an interview with Reuters, the business leader said the company in considering "virtually every opportunity" to expand, both through partnerships and via a planned initial public offering.

"We clearly have an aspiration to come back to the public market over the next couple of years," he said.

Mr Saunders said the firm has an advantage over its competitors due to its sole focus on and dedication to the field of eye health, which allows it to develop innovative products such as a "unique" lens material planned for launch next year.

The chief executive also noted the company's expanded hiring policy in developing markets as a driver of growth, as well as its streamlining initiatives in recent years.

This comes after a number of products launched in the last few weeks, including the lens offerings PureVision2 For Astigmatism and enVista.ADNFCR-8000103-ID-800760689-ADNFCR

Other news stories from 17/10/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd